Nothing Special   »   [go: up one dir, main page]

MA39778A - Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants - Google Patents

Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants

Info

Publication number
MA39778A
MA39778A MA039778A MA39778A MA39778A MA 39778 A MA39778 A MA 39778A MA 039778 A MA039778 A MA 039778A MA 39778 A MA39778 A MA 39778A MA 39778 A MA39778 A MA 39778A
Authority
MA
Morocco
Prior art keywords
gated sodium
sodium channel
channel modulators
sulfonamide compounds
voltage gated
Prior art date
Application number
MA039778A
Other languages
English (en)
Inventor
Moloy Banerjee
Amit Kumar Das
Rajender Kumar Kamboj
Talha Hussain Khan
Rajeshkumar Maganlal Loriya
Venkata P Palle
Vidya Ramdas
Deepak Sahebrao Walke
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MA39778A publication Critical patent/MA39778A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne le composé de formule (i) dans laquelle les substituants sont tels que décrits dans la description, et leur utilisation dans un médicament destiné au traitement de maladies, de troubles associés à l'inhibition des canaux sodiques potentiel-dépendants (vgsc) en particulier na
MA039778A 2014-03-29 2015-03-27 Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants MA39778A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1170MU2014 2014-03-29
IN566MU2015 2015-02-20

Publications (1)

Publication Number Publication Date
MA39778A true MA39778A (fr) 2017-02-08

Family

ID=54239471

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039778A MA39778A (fr) 2014-03-29 2015-03-27 Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants

Country Status (7)

Country Link
US (1) US20170137415A1 (fr)
EP (1) EP3126360A1 (fr)
AU (1) AU2015242219A1 (fr)
CA (1) CA2944115A1 (fr)
MA (1) MA39778A (fr)
TW (1) TW201623264A (fr)
WO (1) WO2015151001A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722938A (zh) 2015-09-04 2017-07-01 魯賓有限公司 作為電位閘控鈉通道調節子之磺醯胺化合物
AR106987A1 (es) 2015-12-18 2018-03-07 Merck Sharp & Dohme Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje
MA46615A (fr) * 2016-10-27 2019-09-04 Bristol Myers Squibb Co Inhibiteurs de nav1.7 de type acyl-sulfonamide
WO2018163077A1 (fr) 2017-03-08 2018-09-13 Lupin Limited Composés indanyle utilisés en tant que modulateurs de canaux sodiques dépendant de la tension
JP2020511511A (ja) * 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
CN110621669A (zh) 2017-05-04 2019-12-27 巴斯夫欧洲公司 防除植物病原性真菌的取代5-卤代烷基-5-羟基异噁唑类
WO2020048828A1 (fr) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft Composés du 5-hétéroaryl-3,9-diazaspiro[5.5]undécane
AR116020A1 (es) 2018-09-03 2021-03-25 Bayer Ag COMPUESTOS DE 3,9-DIAZAESPIRO[5.5]UNDECANO COMO INHIBIDORES DE GGTasa I Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020509A2 (fr) 2000-09-06 2002-03-14 Bayer Aktiengesellschaft Medicament pour lutter contre des maladies virales
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
WO2007109324A2 (fr) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Bloqueurs puissants et sélectifs du canal sodique nav1.7
WO2008046087A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spiro et leurs utilisations en tant qu'agents thérapeutiques
JP2010506853A (ja) 2006-10-12 2010-03-04 ゼノン・ファーマシューティカルズ・インコーポレイテッド 疼痛などのナトリウムチャネル媒介性の疾患の処置のための、スピロ（［３，２−フロ］ピリジン−３，３’−インドール）−２’（１’ｈ）−オン誘導体および関連化合物
TW200833695A (en) 2006-10-12 2008-08-16 Xenon Pharmaceuticals Inc Use of spiro-oxindole compounds as therapeutic agents
WO2008046084A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et utilisation de ceux-ci comme agents thérapeutiques
WO2009012242A2 (fr) 2007-07-13 2009-01-22 Icagen, Inc. Inhibiteurs des canaux sodiques
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
WO2010035166A1 (fr) 2008-09-23 2010-04-01 Pfizer Limited Dérivés de benzamide
WO2010045197A1 (fr) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
SG10201703086VA (en) 2008-10-17 2017-05-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
WO2010053998A1 (fr) 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Dérivés d'indole spiro-condensés utilisables en tant qu'inhibiteurs des canaux sodiques
WO2010078307A1 (fr) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Dérivés de spiro-oxindole en tant que bloqueurs de canaux sodiques
WO2010151597A1 (fr) 2009-06-26 2010-12-29 Schering Corporation Procédés d'utilisation de pyrrolo-benzo-1,4-diazines en tant que bloqueurs de canaux sodiques
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011026240A1 (fr) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Dérivés d'oxopipérazine pour le traitement de la douleur et de l'épilepsie
WO2011056985A2 (fr) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Composés hétérocycliques substitués
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
AU2011218167B2 (en) 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
WO2011140425A1 (fr) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Amides de chromène hétérocyclique-pipéridine spirocyclique utiles comme modulateurs des canaux ioniques
ES2540562T3 (es) 2010-10-05 2015-07-10 Purdue Pharma L.P. Compuestos de quinazolina como bloqueadores de canales de sodio
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
MX2014005068A (es) 2011-10-28 2014-07-30 Merck Sharp & Dohme Compuestos de benzoxazolinona con actividad selectiva en canales de sodio activados por voltaje.
EP2788332A1 (fr) * 2011-12-07 2014-10-15 Amgen, Inc. Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques
US9346798B2 (en) * 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
PE20160548A1 (es) 2013-07-19 2016-05-21 Vertex Pharma Sulfonamidas como moduladores de canales de sodio

Also Published As

Publication number Publication date
TW201623264A (zh) 2016-07-01
US20170137415A1 (en) 2017-05-18
WO2015151001A1 (fr) 2015-10-08
EP3126360A1 (fr) 2017-02-08
AU2015242219A1 (en) 2016-10-06
CA2944115A1 (fr) 2015-10-08

Similar Documents

Publication Publication Date Title
MA39778A (fr) Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX2015017215A (es) Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.
GEP20207102B (en) Sulfonamides as modulators of sodium channels
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
EP3010506A4 (fr) Utilisation de pridopidine à forte dose pour traiter la maladie de huntington
MX364486B (es) Derivados de piridazinona-amidas.
EA201391106A1 (ru) Новые гетероциклические производные
MX2017006382A (es) Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer.
GEP20186903B (en) Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
UY33910A (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC
BR112017010440A2 (pt) administração sublingual de riluzol
EA033250B1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
MX2021001188A (es) Compuesto heterociclico.
MX2016009589A (es) Enonas piridazolilo y pirimidinilo triciclicas sustituidas con arilo y arilalquilo como moduladores de la inflamacion antioxidantes.
BR112017010423A2 (pt) formulação sublingual de riluzol
MX2017005044A (es) Activador de canales de kcnq2-5.
GT201400242A (es) "nuevos compuestos de pirazol"
IN2014MN01469A (fr)
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
IN2014MN02393A (fr)